AMGN Jun 2024 275.000 call
| Previous Close | 9.10 |
| Open | 8.79 |
| Bid | 8.90 |
| Ask | 9.05 |
| Strike | 275.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 8.79 - 9.35 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 118 |
Investor's Business DailyA Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
PR NewswireAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
